Germany · Delayed Price · Currency is EUR Vicore Pharma Holding AB Company Description
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden.
The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension.
It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis.
It has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF.
The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.
| Country | Sweden |
| Founded | 2000 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 29 |
| CEO | Ahmed Mousa |
Contact Details
Address: Kornhamnstorg 53 Stockholm, 111 27 Sweden | |
| Phone | 46 3 17 88 05 60 |
| Website | vicorepharma.com |
Stock Details
| Ticker Symbol | 6Y4 |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ahmed Mousa | Chief Executive Officer |
| Hans Jeppsson | Chief Financial Officer |
| Mikael Nygård | Chief Operating Officer |
| Megan Richards | Head of Investor Relations |